Petros Carvounis, MD
Retina Specialist · Houston, TXNPI 1669527537
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,576 of the $8,325 with a category attached, or 67.0%. 26 manufacturers reported payments, led by AbbVie at 28.4% of the total. Reporting peaked in 2024 at $2,604 and has fallen 70.2% since, to $777 in 2025.
Across 147 payments — averaging $56.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Beaver-visitec International, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Genentech USA, Inc.$545
- Oyster Point Pharma, Inc.$435
- Astellas Pharma US Inc$275
- plus $2K from 20 others
Across 11 payments — averaging $2848.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$31K
What the payments were for
- Consulting fees$2,50030%
- Speaking & faculty fees$2493%
- Food & beverage$5,57667%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $2,363 |
| Beaver-visitec International, Inc. | 2 | $1,307 |
| Regeneron Healthcare Solutions, Inc. | 23 | $1,306 |
| Genentech USA, Inc. | 14 | $545 |
| Oyster Point Pharma, Inc. | 10 | $435 |
| Astellas Pharma US Inc | 6 | $275 |
| Notal Vision, Inc. | 3 | $249 |
| Tarsus Pharmaceuticals, Inc. | 8 | $234 |
| Alimera Sciences, Inc. | 8 | $198 |
| Regeneron | 2 | $183 |
| Dutch Ophthalmic, USA | 2 | $181 |
| Novartis | 5 | $169 |
| Harrow Eye, LLC | 4 | $138 |
| Biogen | 7 | $134 |
| Mallinckrodt Hospital Products Inc. | 4 | $110 |
| Bausch & Lomb Americas Inc. | 3 | $104 |
| Apellis Pharmaceuticals, Inc. | 4 | $85 |
| ANI Pharmaceuticals, Inc. | 2 | $70 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $58 |
| Alcon | 2 | $47 |
| Coherus Oncology, Inc. | 1 | $29 |
| Amgen | 1 | $28 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Dompe US, Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,325 in reported general payments places this provider in the 75th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 54 | $22,429 |
| RestasisCyclosporine | 17 | $17,543 |
| Prednisolone Acetate | 403 | $15,643 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $12,172 |
| LumiganBimatoprost | 15 | $7,461 |
| Difluprednate | 37 | $4,435 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $4,046 |
| Ketorolac Tromethamine | 109 | $3,097 |
| Latanoprost | 303 | $2,383 |
| Timolol Maleate | 255 | $2,257 |
| Brimonidine Tartrate | 250 | $2,080 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 124 | $2,046 |
| Doxycycline Monohydrate | 39 | $1,824 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,537 |
| Tobramycin | 179 | $946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $2,363 | $37,17662 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $24 | $22,42954 claims |
| AlconSimbrinza | $47 | $4,04618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 108 retina specialist providers in Texas.
Other retina specialist in Houston
- Garvin DavisHouston$38K
- Ella LeungHouston$12K
- Lindsey HarrisHouston$10K
- Keith BourgeoisHouston$7K
- Richard FishHouston$5K
- Lee TranHouston$4K
- Michael LamHouston$4K
- John AlappattHouston$4K
- Sapa PhamHouston$4K
- Jie GaoHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.